Cure Alzheimer's Fund is a non-profit organization dedicated to funding research with the highest probability of preventing, slowing or reversing Alzheimer's disease.
For many years, Alzheimer’s disease research was completely stifled by a lack of funding. Pharmaceutical companies were too wary of past failures to fund any new drug development. The drug pipeline was coming up dry, and researchers weren’t encouraged to think big or bold.
Cure Alzheimer’s Fund has helped change that. They are a 501(c)(3) nonprofit organization founded in 2004 by three families frustrated by the slow pace of research. Leveraging their experience in venture capital and corporate start-ups, the founders (Henry McCance, Phyllis Rappaport and Jacqui and Jeff Morby) came together to build a new Alzheimer’s research fund designed to dramatically accelerate research, make bold bets and focus exclusively on finding a cure.
Since its founding, Cure Alzheimer’s Fund has contributed more than $50,000,000 to research, and its funded initiatives have been responsible for several key breakthroughs—including a potential treatment recently selected by the National Institutes of Health (NIH) for its elite “Blueprint” drug discovery program, and the ground-breaking “Alzheimer's in a Dish” study, which promises to greatly accelerate drug testing and was reported by The New York Times as a “giant step forward”.
Cure Alzheimer’s Fund supports some of the best scientific minds in the field of Alzheimer’s research, and it does so without any financial gain for its founders or donors. Fully 100 percent of funds raised by Cure Alzheimer’s Fund go directly to research—the Board of Directors covers all overhead expenses. .Their Research Consortium is an all-star team of scientists working at premier research institutions across the country, regularly conferring with one another on the progress and impediments in their research and constantly sharing their data.
Their goal is to stop Alzheimer’s disease through early prediction, prevention and effective intervention in those patients who have become symptomatic.
Click Here to visit their website
Very challenging 
